Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo + Standard of Care Clear all
Completed Phase 2 Interventional

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

NCT04563026
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC)
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

NCT04502693
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 25 Years
Enrollment
3,657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
64
States / cities
Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 8, 2026, 1:27 AM EDT
Not listed Early Phase 1 Interventional

Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis

NCT02390726
View directory record Official record
Conditions
Ulcerative Colitis, Active Moderate
Interventions
Fecal Microbiota Transplant, Placebo
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers

NCT01594762
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
Topical pexiganan cream 0.8%, Topical placebo cream, Standard wound care
Drug · Other
Lead sponsor
Dipexium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

NCT04221945
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Pembrolizumab, Placebo for pembrolizumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 2Phase 3 Interventional

Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure

NCT00063687
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Oxypurinol
Drug
Lead sponsor
Advanz Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
4
States / cities
Oceanside, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2005 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

Telephone Care Management to Address Sleep Problems in Young Children With Autism

NCT01558180
View directory record Official record
Conditions
Autism Spectrum Disorders, Insomnia
Interventions
Telephone Care Management, Usual Care
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 6 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

NCT02427802
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Infection
Interventions
Gentamicin collagen sponge, Placebo
Drug · Other
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 85 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Mesa, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 8, 2026, 1:27 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Rimegepant, Placebo Comparator, Standard of Care
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Canoga Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 8, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

NCT06061081
View directory record Official record
Conditions
HIV Infections
Interventions
VH3739937, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Bakersfield, California • Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Not applicable Interventional Results available

Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators

NCT02809677
View directory record Official record
Conditions
Asthma, Major Depressive Disorder
Interventions
Non-Interventional
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 70 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care

NCT00829283
View directory record Official record
Conditions
Obesity, Binge Eating
Interventions
Behavioral Weight Loss, Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy, Placebo, Sibutramine/Orlistat
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

NCT04532372
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Leflunomide, Placebo Administration
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 8, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract

NCT01697800
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 8, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

NCT01273064
View directory record Official record
Conditions
Hepatitis C
Interventions
CTS-1027, pegylated interferon, Ribavirin, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 8, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

NCT04680637
View directory record Official record
Conditions
Active Systemic Lupus Erythematosus
Interventions
Efavaleukin Alfa, Placebo, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 8, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions

NCT01845441
View directory record Official record
Conditions
Stroke, Brain Ischemia, Vasospasm, Intracranial, Hemorrhage, Intracranial
Interventions
Dexmedetomidine, Fentanyl, Midazolam
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 8, 2026, 1:27 AM EDT
Recruiting Phase 4 Interventional

Colchicine's Effect on Inflammatory Markers

NCT07287345
View directory record Official record
Conditions
Colchicine, Inflammation in Cardiac Surgery, Post Operative Atrial Fibrillation, Inflammatory Markers, Colchicine Adverse Reaction
Interventions
Colchicine (Colcrys®), Placebo
Drug
Lead sponsor
Ayesha Ather
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

NCT05901831
View directory record Official record
Conditions
Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions
Finerenone, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
28
States / cities
Surprise, Arizona • Stanford, California • Vallejo, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 8, 2026, 1:27 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies

NCT04069195
View directory record Official record
Conditions
Inflammation, Pregnancy Related
Interventions
DHA supplement, Corn Oil: Soybean Oil
Dietary Supplement
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 8, 2026, 1:27 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

NCT04745351
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, RDV Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 8, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery

NCT01888367
View directory record Official record
Conditions
Surgical Site Infections
Interventions
DFA-02 Antibiotic Gel, DFA-02 Placebo Gel
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
31
States / cities
Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 8, 2026, 1:27 AM EDT